Fundamental Analysis of XILIO THERAPEUTICS INC(NASDAQ:XLO) stock

Fundamental Rating

XLO gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 571 industry peers in the Biotechnology industry. XLO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. XLO is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year XLO has reported negative net income.

In the past year XLO has reported a negative cash flow from operations.

XLO had negative earnings in each of the past 5 years.

XLO had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

XLO has a Return On Assets of -72.92%. This is in the lower half of the industry: XLO underperforms 66.84% of its industry peers.

XLO has a Return On Equity of -196.11%. This is in the lower half of the industry: XLO underperforms 68.43% of its industry peers.

		Industry Rank	Sector Rank
ROA	-72.92%
ROE	-196.11%
ROIC	N/A

ROA(3y)-74.51%

ROA(5y)-80.65%

ROE(3y)-110.63%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for XLO so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

The number of shares outstanding for XLO has been increased compared to 1 year ago.

The debt/assets ratio for XLO has been reduced compared to a year ago.

2.2 Solvency

XLO has an Altman-Z score of -7.04. This is a bad value and indicates that XLO is not financially healthy and even has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of -7.04, XLO is doing worse than 68.25% of the companies in the same industry.

There is no outstanding debt for XLO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-7.04

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 2.02 indicates that XLO has no problem at all paying its short term obligations.

XLO has a Current ratio of 2.02. This is in the lower half of the industry: XLO underperforms 75.66% of its industry peers.

A Quick Ratio of 2.02 indicates that XLO has no problem at all paying its short term obligations.

The Quick ratio of XLO (2.02) is worse than 74.60% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.02
Quick Ratio	2.02

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 41.89% over the past year.

EPS 1Y (TTM)41.89%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%63.93%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

XLO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.79% yearly.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y54.34%

EPS Next 2Y33.8%

EPS Next 3Y22.13%

EPS Next 5Y12.79%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

XLO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year XLO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as XLO's earnings are expected to grow with 22.13% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y33.8%

EPS Next 3Y22.13%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

XLO does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

XILIO THERAPEUTICS INC

NASDAQ:XLO (11/22/2024, 8:14:20 PM)

After market: 0.87 -0.02 (-2.47%)

0.892

-0.03 (-3.04%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap39.21M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-72.92%
ROE	-196.11%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.03

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	2.02
Quick Ratio	2.02
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)41.89%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y54.34%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

XILIO THERAPEUTICS INC (XLO)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens